Precision Medicine in Hormone Receptor-Positive Breast Cancer

Frontiers in Oncology
Azadeh NasrazadaniAdrian V Lee

Abstract

In recent decades, breast cancer has become largely manageable due to successes with hormone receptor targeting. Hormone receptor-positive tumors have favorable outcomes in comparison to estrogen receptor (ESR1, ER)/progesterone receptor-negative tumors given the targetable nature of these tumors, as well as their inherently less aggressive character. Nonetheless, treatment resistance is frequently encountered due to a variety of mechanisms, including ESR1 mutations and loss of ER expression. A new era of precision medicine utilizes a range of methodologies to allow real-time analysis of individual genomic signatures in metastases and liquid biopsies with the goal of finding clinically actionable targets. Preliminary studies have shown improved progression-free survival and overall survival with implementation of this information for clinical decision making. In this review, we will discuss the opportunities and challenges in integrating precision medicine through next-generation genomic sequencing into the management of breast cancer.

References

May 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·P CarterH M Shepard
Dec 29, 1988·The New England Journal of Medicine·UNKNOWN Early Breast Cancer Trialists' Collaborative Group
Dec 1, 1993·British Journal of Cancer·I M HarwerthN E Hynes
Aug 4, 1999·Proceedings of the National Academy of Sciences of the United States of America·B Vogelstein, K W Kinzler
May 20, 2000·Annals of the New York Academy of Sciences·M StrounP Anker
Aug 30, 2000·Nature·C M PerouD Botstein
Nov 1, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·I VergoteM von Euler
Nov 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J BonneterreM von Euler
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Nov 6, 2001·Clinica Chimica Acta; International Journal of Clinical Chemistry·M StrounP Anker
Mar 4, 2003·Nature Reviews. Drug Discovery·V Craig Jordan
Jul 8, 2003·The Journal of Pathology·Caroline J WittonJohn M S Bartlett
Jul 15, 2003·Proceedings of the National Academy of Sciences of the United States of America·Devin DressmanBert Vogelstein
Aug 20, 2004·The New England Journal of Medicine·Massimo CristofanilliDaniel F Hayes
May 4, 2005·Clinical Breast Cancer·Robert W Carlson
Mar 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN International Breast Cancer Study GroupRichard D Gelber
Dec 2, 2006·Biochimica Et Biophysica Acta·M Fleischhacker, B Schmidt
Dec 29, 2006·The New England Journal of Medicine·Charles E GeyerDavid Cameron
Feb 10, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sabine RiethdorfKlaus Pantel
Aug 2, 2008·Nature Medicine·Frank DiehlLuis A Diaz
Apr 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Elizabeth H HammondAntonio C Wolff
Aug 11, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W Fraser SymmansLajos Pusztai
Sep 30, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Henry K LinRichard J Cote
Oct 5, 2010·Annual Review of Medicine·C Kent Osborne, Rachel Schiff
Oct 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel D Von HoffRobert Penny
Dec 14, 2011·The New England Journal of Medicine·José BaselgaUNKNOWN CLEOPATRA Study Group
Jun 1, 2012·Science Translational Medicine·Tim ForshewNitzan Rosenfeld
Oct 2, 2012·The New England Journal of Medicine·Sunil VermaUNKNOWN EMILIA Study Group
Dec 1, 2012·Science Translational Medicine·Rebecca J LearyVictor E Velculescu
Mar 15, 2013·The New England Journal of Medicine·Sarah-Jane DawsonNitzan Rosenfeld

❮ Previous
Next ❯

Citations

Apr 21, 2020·Expert Review of Proteomics·Aurora S BlucherYiu Huen Tsang
May 31, 2020·Cells·Filippo Acconcia
Dec 14, 2018·Frontiers in Oncology·Jesse M Mast, Periannan Kuppusamy
Nov 8, 2020·European Journal of Medicinal Chemistry·Tingting LiuJifu Hao
Feb 18, 2020·Trends in Cancer·Ashkan ShahbandiJames G Jackson
Apr 30, 2021·Frontiers in Immunology·Shuvasree SenGuptaCarole A Parent
Aug 23, 2021·Journal of Hematology & Oncology·Hui HuaYangfu Jiang

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies
biopsy

Software Mentioned

ExteNET
IMAGE
Cell Search

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.